U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. For Consumers
  3. Women's Health
  4. OWH Education and Training
  5. Women's Health Events
  6. Previous OWH Events
  1. Women's Health Events

Previous OWH Events

From the FDA Office of Women's Health

Image
Woman watching program on laptop

On this page: Recent OWH events 

Recent OWH events

The FDA Office of Women’s Health (OWH) teams with various FDA collaborators and external partners to offer scientific and educational events on a variety of women’s health topics. When possible, we publicly post recordings of previous events. 

Please also see our Continuing Education (CE) page for a list of event recordings offering CE for health professionals. Don’t miss upcoming OWH events!

OWH hosted a webinar featuring guest speaker, Titilope Fasipe, MD, PhD, Co-Director, Sickle Cell & Thalassemia Program, Texas Children’s Hospital. The webinar discussed the clinical characteristics of sickle cell disease (SCD), advances in medical therapies to treat SCD, and the unique factors impacting women living with SCD. Dr. Fasipe explained the role of historical and systemic disparities on SCD health outcomes with emphasis on the impact on women, and discussed the consequences of national and state health policy initiatives on SCD.

In observance of National Women's Health Week (NWHW) 2024 and National Osteoporosis Awareness and Prevention month, the FDA Office of Women’s Health (OWH), hosted a free virtual public webinar titled: Osteoporosis: A perspective for 2024 presented by Marcella Donovan Walker, MD, MS. Professor of Medicine at Columbia University Medical Center. The lecture summarized the current approach to assessing bone health, as well as preventing and treating osteoporosis with a focus on postmenopausal women.

OWH hosted a Speaker Series lecture featuring Dr. Khalil Ghanem, Professor of Medicine in the Division of Infectious Diseases at Johns Hopkins University School of Medicine. In this lecture, Dr. Ghanem reviewed the epidemiology, clinical presentation, diagnostic approach, and treatment of the common and curable sexually transmitted infections in cis-gender women. Dr. Ghanem also highlighted some important gaps in knowledge that, if filled, can help enhance reproductive health outcomes in this population. (Recording: FDA YouTube, 1 hour)

OWH, in collaboration with the Center for Drug Evaluation and Research (CDER) Office of Clinical Pharmacology (OCP), hosted a free public workshop including presentations and session discussions by experts in the fields of clinical pharmacology, obstetrics and gynecology, endocrinology, and clinical care. Speakers discussed the current understanding of the impact of menopause on the pharmacokinetics and pharmacodynamics (the movement of drugs through the body, and the body’s biological response to drugs, respectively), and exposure-response relationships of FDA-regulated drugs and biologics used by menopausal women for non-menopause-related indications. (Recording: Zoom, 3 hours, 17 minutes) 

OWH and the Johns Hopkins Center of Excellence in Regulatory Science and Innovation held a virtual public workshop to discuss the role of real-world data (RWD) to understand medication use in pregnancy and lactation. Panels discussed ways to address knowledge gaps, opportunities, and challenges of collecting RWD, and current regulatory perspectives on the collection and potential use of RWD. (Recording: JHU/YouTube, 4 hours, 27 minutes)

OWH held a public webinar focused on COVID-19 Vaccines & Women with Dr. Kaveeta Vasisht, FDA’s Associate Commissioner for Women’s Health and Dr. Peter Marks, Director of FDA’s Center for Biologics Evaluation and Research (CBER). This webinar aimed to provide our stakeholders with up-to-date information and address questions regarding the COVID-19 vaccines and their use in women. (Recording: FDA YouTube, 1 hour)

OWH hosted a public meeting to highlight scientific evidence and knowledge gaps about sex and gender differences in cannabidiol (CBD) use and responses. Panel topics included: Perspectives from Patients and Healthcare Professionals, Sex Differences in the Effects of Cannabinoids, Use of CBD and Other Cannabinoids in Pregnancy, and Government Agency Perspectives on CBD Research and Evaluation. (Recording: FDA, 5 hours, 47 minutes)

OWH together with FDA’s Center for Drug Evaluation and Research (CDER) and Center for Tobacco Products (CTP), hosted a 2-day public meeting to discuss sex and gender differences in prescription opioid use and pain neurobiology. The meeting brought together 40 nationally and internationally recognized clinicians and scientists to highlight evidence and share insights on sex and gender differences related to opioid and nicotine use, abuse, and recovery. (Day 1 recording: FDA, 6 hours, 6 minutes; Day 2 recording: FDA, 5 hours, 36 minutes)

 

Back to Top